DCLK1 and neoplasm: Consistent with the in vitro results, a series of transplantation assays performed in HCT116 xenograft mouse models (Figure 6D) showed that DCLK1-IN-1 treatment attenuated both primary and secondary tumor growth without any significant changes in mouse body weight (Figure S12A) or, obvious clinical signs, including anorexia, salivation, diarrhea, vomiting, polyuria, anuria and fecal alterations and serological parameters of liver and kidney toxicity (Figure S12B).